Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1321038 | 0.84 | LMNA (0.43) | KDM4EALDH1A1LMNATLR8TLR7 | |
| Hydrochloric Acid SCHEMBL27681044 | 0.82 | LMNA (0.42) | KDM4EALDH1A1LMNATLR8TLR7 | |
| Hydrochloric Acid SCHEMBL6831032 | 0.82 | LMNA (0.42) | KDM4EALDH1A1LMNATLR8TLR7 | |
| SCHEMBL17480006 | 0.80 | TLR8 (0.42) | KDM4EALDH1A1LMNATLR8TLR7 | |
| SCHEMBL559332 | 0.80 | KDM4E (0.40) | KDM4EALDH1A1LMNATLR8TLR7 | |
| SCHEMBL1143403 | 0.80 | ALDH1A1 (0.40) | KDM4EALDH1A1LMNATLR8TLR7 | |
| SCHEMBL30420099 | 0.80 | ALDH1A1 (0.40) | KDM4EALDH1A1LMNATLR8TLR7 | |
| SCHEMBL9644113 | 0.79 | ALDH1A1 (0.50) | KDM4EALDH1A1LMNATLR8TLR7 | |
| SCHEMBL9287279 | 0.76 | TLR8 (0.53) | KDM4EALDH1A1LMNATLR8TLR7 | |
| SCHEMBL15508426 | 0.76 | TLR8 (0.44) | KDM4EALDH1A1LMNATLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105073742-B | FLAP conditioning agents | 詹森药业有限公司 | 2017-08-08 | — | — | CN | claimed |
| CN-105073742-A | Flap modulators | JANSSEN PHARMACEUTICA NV | 2015-11-18 | — | — | CN | claimed |
| EP-4656602-A2 | MEMBRANES FOR REMOVING METALLIC SPECIES FROM AMINES | Entegris, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2025227032-A1 | METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20240350984-A1 | MEMBRANES FOR REMOVING METALLIC SPECIES FROM AMINES | ENTEGRIS, INC. | 2024-10-24 | — | — | US | disclosed |
| US-20240270737-A1 | SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE | STINGINN INC. (US) | 2024-08-15 | — | — | US | disclosed |
| US-12059656-B2 | Membranes for removing metallic species from amines | ENTEGRIS, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4221872-A1 | MEMBRANES FOR REMOVING METALLIC SPECIES FROM AMINES | Entegris, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| CN-114377565-A | Membranes for removal of metal species from amines | 恩特格里斯公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20220105476-A1 | Membranes for Removing Metallic Species from Amines | ENTEGRIS, INC. | 2022-04-07 | — | — | US | disclosed |
| EP-1826001-B1 | A heat-sensitive positive-working lithographic printing plate precursor | AGFA GRAPHICS NV (BE) | 2011-07-06 | — | — | EP | disclosed |
| US-20110097349-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-28 | — | — | US | disclosed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | disclosed |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
| CN-1004756-B | Process for preparing compounds | 菲索斯公立有限公司 | 1989-07-12 | — | — | CN | disclosed |
| EP-0023140-B1 | HERBICIDAL SULFONAMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THEM | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-10-31 | — | — | EP | disclosed |
| US-4424073-A | N-(PYRIMIDINYLAMINOCARBONYL/SULFONAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-01-03 | — | — | US | disclosed |
| US-4342587-A | Herbicidal pyridinsulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-08-03 | — | — | US | disclosed |
| EP-0023140-A2 | Herbicidal sulfonamides, preparation and use thereof, and compositions containing them | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270737-A1 | SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE | STING1, IRF3, MAVS | KDM4E 2288/4885ALDH1A1 4812/4885LMNA 2811/4885 |
| US-20110097349-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | KDM4E 3769/4885ALDH1A1 4026/4885LMNA 1065/4885 |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | KDM4E 3769/4885ALDH1A1 4026/4885LMNA 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.